Cargando…

In the blood: biomarkers for amyloid pathology and neurodegeneration in Alzheimer’s disease

This scientific commentary refers to ‘Plasma total-tau, neurofilament light chain and amyloid-β levels and risk of dementia: a population-based study’ by de Wolf et al. (https://doi.org/10.1093/brain/awaa054), and ‘Relationship of amyloid-b1–42 in blood and brain amyloid: Ginkgo Evaluation of Memory...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toombs, Jamie, Zetterberg, Henrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Scientific Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425323/ https://www.ncbi.nlm.nih.gov/pubmed/32954304 http://dx.doi.org/10.1093/braincomms/fcaa054

Ejemplares similares

Is phosphorylated tau a good biomarker of synapse pathology in Alzheimer’s disease?
por: Saura, Carlos A, et al.
Publicado: (2023)

Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration
por: Höglund, K, et al.
Publicado: (2017)

Genetic Variants and Related Biomarkers in Sporadic Alzheimer’s Disease
por: Guerreiro, Rita, et al.
Publicado: (2014)

Correction: Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration
por: Höglund, K., et al.
Publicado: (2018)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

Spitting image: can saliva biomarkers reflect Alzheimer's disease?
por: Ashton, Nicholas J., et al.
Publicado: (2021)

The Dichotomy of Alzheimer’s Disease Pathology: Amyloid-β and Tau
por: Ashford, J. Wesson
Publicado: (2019)

An anti-amyloid therapy works for Alzheimer’s disease: why has it taken so long and what is next?
por: Hardy, John, et al.
Publicado: (2023)

Do genetic factors contribute to sex-specific differences in resilience to amyloid pathology?
por: Groot, Colin, et al.
Publicado: (2022)

Blood amyloid-β oligomerization associated with neurodegeneration of Alzheimer’s disease
por: Youn, Young Chul, et al.
Publicado: (2019)

Amyloid-beta 42 adsorption following serial tube transfer
por: Toombs, Jamie, et al.
Publicado: (2014)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020)

Cohort study of electroencephalography markers of amyloid-tau-neurodegeneration pathology
por: Tanabe, Sean, et al.
Publicado: (2020)

Neurofilament light chain: defining the analyte
por: Leckey, Claire A., et al.
Publicado: (2022)

Blood-based molecular biomarkers for Alzheimer’s disease
por: Zetterberg, Henrik, et al.
Publicado: (2019)

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease
por: Lewczuk, Piotr, et al.
Publicado: (2018)

Alzheimer’s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint
por: Alawode, Deborah O. T., et al.
Publicado: (2022)

Amyloid precursor protein: more than just neurodegeneration
por: Pimplikar, Sanjay W, et al.
Publicado: (2011)

Plasma p-tau217: from ‘new kid’ to most promising candidate for Alzheimer’s disease blood test
por: Teunissen, Charlotte E, et al.
Publicado: (2020)

Effects of pre‐analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Molecular biomarkers of Alzheimer's disease: progress and prospects
por: Lashley, Tammaryn, et al.
Publicado: (2018)

Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration
por: Gonzalez-Ortiz, Fernando, et al.
Publicado: (2022)

Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease
por: Ferrari-Souza, João Pedro, et al.
Publicado: (2022)

Amyloid imaging in prodromal Alzheimer's disease
por: Ossenkoppele, Rik, et al.
Publicado: (2011)

Music, memory and mechanisms in Alzheimer’s disease
por: Clark, Camilla N., et al.
Publicado: (2015)

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Candesartan—the next anti-amyloid drug?
por: Yasar, Sevil
Publicado: (2022)

Concatenating plasma p-tau to Alzheimer’s disease
por: Tijms, Betty M, et al.
Publicado: (2021)

Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia
por: Shen, Xue‐Ning, et al.
Publicado: (2020)

Alzheimer’s disease, cerebrovascular disease and dementia: lump, split or integrate?
por: Biessels, Geert Jan
Publicado: (2022)

Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease
por: Andersson, Emelie, et al.
Publicado: (2020)

Blood Biomarkers for Alzheimer’s Disease in Down Syndrome
por: Montoliu-Gaya, Laia, et al.
Publicado: (2021)

Detecting early changes in Alzheimer’s disease with graph theory
por: Pereira, Joana B
Publicado: (2020)

Amyloid blood biomarker detects Alzheimer's disease
por: Nabers, Andreas, et al.
Publicado: (2018)

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
por: Palmqvist, Sebastian, et al.
Publicado: (2015)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome
por: Strydom, Andre, et al.
Publicado: (2018)

Blood biomarkers and neurodegeneration in individuals exposed to repetitive head impacts
por: Bernick, Charles, et al.
Publicado: (2023)

Preclinical Alzheimer’s disease: how to predict who will decline next year?
por: Hanseeuw, Bernard J, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9lcaf86ec0c4c126g6ej1hdmo0